HC Wainwright assumed coverage on shares of Alpha Cognition (NASDAQ:ACOG - Free Report) in a report published on Tuesday, Marketbeat Ratings reports. The firm issued a buy rating and a $20.00 price target on the stock. HC Wainwright also issued estimates for Alpha Cognition's Q1 2025 earnings at ($0.72) EPS, Q2 2025 earnings at ($0.52) EPS, Q3 2025 earnings at ($0.57) EPS, Q4 2025 earnings at ($0.54) EPS, FY2025 earnings at ($2.02) EPS, Q1 2026 earnings at ($0.51) EPS, Q2 2026 earnings at ($0.45) EPS, Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.29) EPS and FY2026 earnings at ($1.67) EPS.
Alpha Cognition Stock Performance
Shares of NASDAQ ACOG traded down $0.18 during mid-day trading on Tuesday, reaching $5.37. The company had a trading volume of 63,805 shares, compared to its average volume of 81,930. Alpha Cognition has a one year low of $4.66 and a one year high of $7.00. The company has a 50-day moving average price of $5.90. The firm has a market cap of $86.03 million, a price-to-earnings ratio of -2.10 and a beta of 2.50.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Solas Capital Management LLC bought a new position in Alpha Cognition in the fourth quarter valued at about $8,096,000. Sphera Funds Management LTD. bought a new position in Alpha Cognition in the fourth quarter valued at about $3,652,000. Alyeska Investment Group L.P. bought a new position in Alpha Cognition in the fourth quarter valued at about $2,356,000. Altium Capital Management LLC bought a new position in Alpha Cognition in the fourth quarter valued at about $1,620,000. Finally, Rosalind Advisors Inc. acquired a new stake in shares of Alpha Cognition during the fourth quarter valued at about $1,489,000.
Alpha Cognition Company Profile
(
Get Free Report)
Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.
See Also
Before you consider Alpha Cognition, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Cognition wasn't on the list.
While Alpha Cognition currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
